Provista Diagnostics
Provista Diagnostics is a privately held New York–based diagnostics company founded in 2007 that develops and commercializes blood-based diagnostic tests for the detection of oncology-related diseases, operating with 11–50 employees.
- Company typePrivate
- Founded2007
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Provista Diagnostics does
Provista Diagnostics is a privately held, for-profit diagnostics company founded in 2007 and headquartered in New York, United States. The company develops and commercializes blood-based diagnostic tests for the detection of oncology-related diseases, placing it in the liquid biopsy / oncology diagnostics segment of the clinical laboratory industry. The company operates at a small scale, with a disclosed headcount range of 11–50 employees.
Between March 2012 and March 2016, Provista Diagnostics completed seven disclosed equity financing rounds totaling approximately $34.5 million, with individual rounds ranging from roughly $2.5 million to $6.05 million. Investor names, lead investors, and valuation data are not disclosed in the available records. No commercial revenue, product pricing, distribution channels, regulatory milestones, or customer relationships are documented in the input data, and no funding activity is disclosed after March 2016.
The leadership team comprises Uriel E. Kusiatin as Chief Executive Officer, Philippe J. Goix as Chief Commercial Officer, and John N. Fermanis as Chief Financial Officer. The CCO and CFO appointments, combined with the funding cadence through 2016, suggest a period of commercial and financial build-out during that window; however, the absence of post-2016 disclosures limits visibility into current operations, product pipeline status, and commercial traction.
Provista Diagnostics firmographics
Firmographics- Name
- Provista Diagnostics
- Website
- https://provistadx.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Provista Diagnostics is a privately held New York–based diagnostics company founded in 2007 that develops and commercializes blood-based diagnostic tests for the detection of oncology-related diseases, operating with 11–50 employees.
- Ownership category
- akta.pro rank
Provista Diagnostics industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where Provista Diagnostics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Provista Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Provista Diagnostics product offering
Product offeringCore offering
Provista Diagnostics develops and commercializes blood-based diagnostic tests for the detection of oncology-related diseases. The company creates diagnostic assays that use blood samples to identify cancer-related conditions, providing healthcare providers with diagnostic tools for oncology applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Blood-based diagnostic tests for oncology Blood-based diagnostic tests designed for the detection of oncology-related diseases. The tests are developed and commercialized for use in clinical settings to support cancer diagnosis and detection through blood sample analysis.
Companies that use Provista Diagnostics
Customer profileIdeal customer profiles1 record
Provista Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Provista Diagnostics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights2 records
Provista Diagnostics competitors and assessment
Company assessmentDirect peers
- Guardant Health: Leading blood-based oncology diagnostics company offering liquid-biopsy tests for therapy selection, MRD, and screening. Directly comparable to Provista in targeting oncology blood-based biomarker assays for clinicians.
- Natera: Commercial-stage molecular diagnostics company with a meaningful oncology liquid-biopsy franchise (e.g., Signatera MRD) — directly competes in blood-based oncology testing using cfDNA/ctDNA approaches.
- Exact Sciences: Commercial diagnostics company with Cologuard and an expanding oncology blood-test pipeline (Oncotype, Previstage, Thrive-acquired assets). Comparable as a blood-and-stool-based oncology diagnostics platform.
- Biodesix: Blood-based diagnostics company focused on oncology (e.g., VeriStrat, GeneStrat, Nodify Lung). Closely comparable to Provista in clinical blood-based oncology biomarker assay development and commercialization.
- Personal Genome Diagnostics (acquired by NeoGenomics): Cancer genomics company offering blood- and tissue-based tumor profiling and MRD tests. Comparable to Provista as a blood-based oncology diagnostics peer in the ctDNA/MRD space.
Broad incumbents
- NeoGenomics: Specialty oncology-focused reference laboratory with broad hematology, solid-tumor, and liquid-biopsy offerings. Comparable as a clinical-laboratory services competitor in oncology diagnostics.
- Veracyte: Genomic diagnostics company expanding into oncology risk stratification and liquid-biopsy-adjacent tests. Comparable as a molecular oncology diagnostics commercial player with menu-extension strategy.
Others
- Bio-Techne: Reagent, antibody, and diagnostic-kit provider serving oncology and life-science researchers. Comparable as an upstream enabler of blood-based biomarker assay development.
Emerging players
- ANGLE plc: Liquid-biopsy company commercializing the Parsortix CTC platform for oncology and other indications. Comparable as a smaller-cap blood-based oncology diagnostics peer focused on circulating tumor cells.
- Freenome: Multiomics blood-based early-detection oncology diagnostics company. Comparable as a peer in the blood-based oncology screening/detection category Provista is targeting.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Provista Diagnostics social profiles
Digital presenceProvista Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Provista Diagnostics leadership team
Management profileNumber of profiles
Profiles3 records
Provista Diagnostics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Provista Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Provista Diagnostics
What does Provista Diagnostics do?
Provista Diagnostics develops and commercializes blood-based diagnostic tests for the detection of oncology-related diseases. The company creates diagnostic assays that use blood samples to identify cancer-related conditions, providing healthcare providers with diagnostic tools for oncology applications.
When was Provista Diagnostics founded?
Provista Diagnostics was founded in 2007. It employs 11 to 50 people.
Where is Provista Diagnostics based?
Provista Diagnostics is headquartered in New York, United States, in the North America region.
Who are Provista Diagnostics's main competitors?
Direct peers on record are Guardant Health, Natera, Exact Sciences, Biodesix and Personal Genome Diagnostics (acquired by NeoGenomics). Broad incumbents are NeoGenomics and Veracyte. Bio-Techne is listed as an others. Emerging players are ANGLE plc and Freenome.
Does Provista Diagnostics have an API?
No public API is recorded for Provista Diagnostics.
What industry is Provista Diagnostics in?
Provista Diagnostics's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 325413 and its SIC code is 2835.